Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies.
作者信息
Loh Jerold, Ang Yvonne Li En, Jain Amit, Yeong Joe, Sundar Raghav
机构信息
Department of Haematology-Oncology, National University Cancer Institute, Singapore.
Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
出版信息
JCO Precis Oncol. 2022 Jul;6:e2200208. doi: 10.1200/PO.22.00208.
Abstract
摘要
相似文献
1
Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies.靶向胃肠道原发性恶性肿瘤中的间变性淋巴瘤激酶
JCO Precis Oncol. 2022 Jul;6:e2200208. doi: 10.1200/PO.22.00208.
2
ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma.伴有JAK2重排的ALK阴性间变性大细胞淋巴瘤，酷似经典型霍奇金淋巴瘤。
Blood. 2023 Apr 27;141(17):2160. doi: 10.1182/blood.2022019468.
3
Characterization of secondary GI lesions with anaplastic large-cell (Ki-1) lymphoma: a first report of two cases.间变性大细胞（Ki-1）淋巴瘤继发胃肠道病变的特征：两例首例报告
Gastrointest Endosc. 2005 Apr;61(4):607-9. doi: 10.1016/s0016-5107(04)02785-3.
4
[Anaplastic lymphoma kinase positive anaplastic large cell lymphoma with cardiac infiltration: a case report].[间变性淋巴瘤激酶阳性的间变性大细胞淋巴瘤伴心脏浸润：一例报告]
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):351-352. doi: 10.3760/cma.j.cn112152-20200226-00134.
5
Teaching NeuroImage: Branching Dura Mater in Primary CNS ALK-Positive Anaplastic Large Cell Lymphoma.教学神经影像：原发性中枢神经系统ALK阳性间变性大细胞淋巴瘤中的硬脑膜分支
Neurology. 2023 Oct 24;101(17):766-768. doi: 10.1212/WNL.0000000000207752. Epub 2023 Aug 3.
6
Leukemic phase of ALK-positive anaplastic large cell lymphoma.ALK阳性间变性大细胞淋巴瘤的白血病期
Blood. 2013 Mar 14;121(11):1934. doi: 10.1182/blood-2012-11-465369.
7
The elusive but classic presentation of small cell variant of ALK+ anaplastic large cell lymphoma (ALCL).ALK阳性间变性大细胞淋巴瘤（ALCL）小细胞变异型难以捉摸却又典型的表现。
Am J Hematol. 2023 Feb;98(2):368-370. doi: 10.1002/ajh.26394. Epub 2021 Nov 13.
8
BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤中BCL-3的过表达
Blood. 2003 Aug 1;102(3):1146-7. doi: 10.1182/blood-2003-04-1366.
9
Genetics of anaplastic large cell lymphoma.间变性大细胞淋巴瘤的遗传学
Leuk Lymphoma. 2016;57(1):21-7. doi: 10.3109/10428194.2015.1064530. Epub 2015 Jul 21.
10
Primary gastrointestinal anaplastic large cell lymphoma.原发性胃肠道间变性大细胞淋巴瘤
Pathology. 2017 Aug;49(5):479-485. doi: 10.1016/j.pathol.2017.05.007. Epub 2017 Jul 8.
本文引用的文献
1
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.ALK 抑制剂在 ALK 融合阳性胃肠道癌症患者中的应用：国际数据集和分子病例系列。
JCO Precis Oncol. 2022 Apr;6(1):e2200015. doi: 10.1200/PO.22.00015.
2
Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy.解读肿瘤异质性：从组织活检到液体活检
Cancers (Basel). 2022 Mar 8;14(6):1384. doi: 10.3390/cancers14061384.
3
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶（<I>ALK</I>）重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
4
ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report.伴有脑转移的ALK重排阳性胰腺癌对ALK抑制剂有显著反应：一例报告
Front Oncol. 2021 Sep 6;11:724815. doi: 10.3389/fonc.2021.724815. eCollection 2021.
5
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.胃肠道肿瘤免疫编辑和免疫检查点抑制耐药中的表观遗传启动子改变。
Gut. 2022 Jul;71(7):1277-1288. doi: 10.1136/gutjnl-2021-324420. Epub 2021 Aug 25.
6
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.非小细胞肺癌中的致癌驱动基因突变：过去、现在与未来
World J Clin Oncol. 2021 Apr 24;12(4):217-237. doi: 10.5306/wjco.v12.i4.217.
7
Immunotherapy for -Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches.针对重排非小细胞肺癌的免疫疗法：挑战孕育有前景的方法。
Cancers (Basel). 2021 Mar 23;13(6):1476. doi: 10.3390/cancers13061476.
8
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.晚期胆管癌二线FOLFOX化疗与积极症状控制的对比研究（ABC-06）：一项3期、开放标签、随机对照试验
Lancet Oncol. 2021 May;22(5):690-701. doi: 10.1016/S1470-2045(21)00027-9. Epub 2021 Mar 30.
9
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.有驱动基因改变的 IV 期非小细胞肺癌的治疗：ASCO 和 OH（CCO）联合指南更新。
J Clin Oncol. 2021 Mar 20;39(9):1040-1091. doi: 10.1200/JCO.20.03570. Epub 2021 Feb 16.
10
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.西米普利单抗单药治疗 PD-L1 表达水平至少为 50%的晚期非小细胞肺癌的一线治疗：一项多中心、开放标签、全球、3 期、随机、对照临床试验。
Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2.
Zotero 插件